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Abstract
Background: No agreement has been reached for the best surgical treatment for patients with chronic ischemic
mitral regurgitation (IMR) undergoing coronary artery bypass grafting (CABG). Our objective was to meta-analyze
the clinical outcomes of repair and replacement.
Methods: A computerized search was performed using Pubmed, Embase, Ovid medline and Cochrane Library. The
search terms “ischemic or ischaemic” and “mitral valve” and “repair or replacement or annuloplasty” and “coronary
artery bypass grafting” were entered as MeSH terms and keywords. The primary outcomes were operative mortality
and late mortality. Secondary outcomes were 2+ or greater recurrence of mitral regurgitation and reoperation rate.
Results: Eleven studies were eligible for the final meta-analysis. These studies included a total of 1750 patients, 60.
4 % of whom received mitral valve repair. All patients underwent concomitant coronary artery bypass graft. No
differences were found in operative mortality (summary odds ratio [OR] 0.65; 95 % confidence interval [CI] 0.43-1.00;
p = 0.05), late mortality (summary hazard ratio [HR] 0.87; 95 % confidence interval [CI] 0.67-1.14; p = 0.31) and
reoperation (summary odds ratio [OR] 1.47; 95 % confidence interval [CI] 0.90-2.38; p = 0.12). Regurgitation recurrence
was lower in the replacement group (summary odds ratio [OR] 5.41; 95 % confidence interval [CI] 3.12-9.38; p < 0.001).
Conclusion: In patients with chronic ischemic mitral regurgitation during CABG, mitral valve replacement is associated
with lower recurrence of regurgitation. No differences were found regarding survival and reoperation rates.
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Meta-analysis
Background
Chronic ischemic mitral regurgitation (IMR) is a frequent
and important complication after myocardial infarction.
Its pathophysiologic mechanisms account for remodeling
of segmental/global left ventricle (LV) inducing papillary
muscle displacement and leaflet tethering [1]. The pres-
ence of IMR is independently associated with mortality
and morbidity after myocardial infarction [2].
Given the severity of IMR, surgery performed for IMR
ranges from coronary artery bypass grafting (CABG) alone
to both CABG and mitral valve surgery [3, 4]. Two ran-
domized trials indicated that repair was associated with a
reduced prevalence of mitral regurgitation but did not
show a clinically meaningful advantage of adding mitral
valve repair to CABG [5, 6]. In addition, when compared
with replacement, previous meta-analyses concluded that
repair is associated with lower operative mortality but
higher recurrence of regurgitation in patients with ische-
mic mitral regurgitation, with or without CABG [7, 8]. For
patients with chronic IMR undergoing combined CABG,
the best surgical treatment is still controversial. Some
studies support replacement [9, 10], others support repair
[11, 12], and others showed similar survival for the two
procedures [13]. Current guidelines recommend mitral
valve surgery for severe IMR, but do not demonstrate a
specific type of procedure [14, 15]. Numerous non-
randomized studies have been published comparing the
clinical outcomes between MVP +CABG and MVR +
CABG for IMR. However, there is still no systematic and
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quantitative assessment of accumulated literature on this
topic. Meta-analysis is a powerful tool to provide mean-
ingful comparison of short and long-term outcomes of
these procedures. The present meta-analysis aimed to
assess the clinical outcomes of patients who underwent
mitral valve surgery and CABG for chronic IMR.
Methods
Search strategy
This meta-analysis was conducted according to the rec-
ommendations of the Meta-Analysis of Observational
Studies in Epidemiology (MOOSE) [16]. A computerized
search was performed using Pubmed, Embase, Ovid
medline and Cochrane Library from their dates of incep-
tion to December 2015 without language restriction.
The search terms “ischemic or ischaemic” and “mitral
valve” and “repair or replacement or annuloplasty” and
“coronary artery bypass grafting” were entered as MeSH
terms and keywords. The language of publication was
restricted to English. We also reviewed the full text and
references lists of all relevant review articles in detail. YW
and XS independently undertook the literature search,
screening of titles and abstracts. Any disagreement was re-
solved by consensus.
Study selection
Articles were included if there is a direct comparison of
repair versus replacement and all patients with IMR had
CABG. The exclusion criteria were applied to select the
final articles for the meta-analysis: (1) ischemic etiology in
only a subset of the patients with outcomes not specifically
provided (2) nonischemic dilated cardiomyopathy (3) beat-
ing heart procedures (4) concomitant surgical ventricular
restoration (5) preoperative hemodynamic instability (6)
lack of annuloplasty in > 20 % of the patients in the repair
group (7) acute IMR.
Data extraction and quality assessment
All data were extracted independently by 2 investigators
(Y.W., X.S.) according to the prespecified selection cri-
teria, with disagreement resolved by consensus among
all authors. The following data from each study were
extracted: the last name of the first author, year of
publication, study population, patients’ age and gender,
comorbidities, cardiac function, severity of mitral regur-
gitation at baseline and follow-up period. Any disagree-
ment was resolved by consensus.
Based on the extracted data, the quality of the in-
cluded studies was evaluated using the nine-item
Newcastle-Ottawa Quality scale [17], a widely used tool
for the quality assessment of non-randomized trials. The
high-quality study was defined as a study with ≥6 scores.
Statistical analysis
The primary end points were operative mortality and
late mortality (considered to be year after operation).
Operative mortality was defined as death within 30 days
after operation or in-hospital death. Secondary end points
were MR recurrence 2+ or greater and reoperation at
follow-up. The meta-analysis was performed using Review
Manager (Revman, version 5.3 for windows, Oxford,
England, Cochrane Collaboration) and Stata (version 11.0;
StataCorp, College Station, TX). Hazard ratio (HR) with a
95 % confidence intervals (CIs), directly extracted from
these included studies or indirectly calculated using the
method of Tierney and colleagues [18] to assess the
efficacy of the surgical intervention in each study. A sum-
mary of odds ratio (OR) and their corresponding 95 % CI
were computed for each dichotomous outcome using ei-
ther fixed-effects models or, in the presence of substantial
heterogeneity (I2 > 50 %), random-effects models [19].
Statistical heterogeneity across studies was examined with
Cochran’s Q test as well as the I2 statistics. Studies with an
I2 statistics of <25 % were considered to have low hetero-
geneity, those with an I2 statistics of 25–50 % were consid-
ered to have moderate heterogeneity, and those with an I2
statistics of >50 % were considered to have a high degree
of heterogeneity [20]. If there was high heterogeneity, the
possible clinical and methodological factors for this were
further explored. Potential sources of heterogeneity
were investigated using sensitivity analyses and each
study involved in the meta-analysis was excluded each
time to reflect the influence of the individual data set
on the pooled RRs.
Publication bias was assessed using the Egger regression
asymmetry test [21] and Begg adjusted rank correlation
test [22]; a P value of less than 0.05 was considered repre-
sentative of statistically significant publication bias. Meta-
analysis results are displayed in forest plots. A p value <
0.05 was considered statistically significant.
Results
Search results and study quality
The literature search identified a total of 545 studies,
which were published between 1965 and 2015. On the
basis of title and abstracts, 34 articles were selected and
reviewed in full. Eleven articles met the inclusion and ex-
clusion criteria [9–13, 23–28] (Fig. 1). Of the included
studies, there were ten retrospective observational studies
[9–13, 23–27] and one prospective observational study
[28]. All were nonrandomized studies. These studies in-
cluded a total of 1807 patients, 1091 (60.4 %) of whom
underwent repair and 716 (39.6 %) of whom underwent
replacement. All patients had CABG. Patient characteris-
tics and a summary of operative details are summarized in
Tables 1 and 2, respectively. With the exception of the re-
placement patients being older in 2 of the studies, the two
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groups were similar in terms of hypertension (HTN),
diabetes, atrial fibrillation (AF), left ventricular ejection
fraction (LVEF) and the New York Heart Association
(NYHA) class. Eight of the studies reported data on the
type of prosthesis used for mitral valve replacement and
preservation of the subvalvular apparatus. In half of the
studies, the majority of patients received a bioprothesis
valve. In addition, preservation of the subvalvular (either
total or partial) apparatus were performed in the vast ma-
jority of mitral valve replacements.
All the eleven trials were assessed by the Newcastle-
Ottawa Scale for quality assessment risk evaluation of
adequacy of selection, comparability, and outcomes
assessment for individual trials (Table 3). All studies
included in our meta-analysis were of high-quality
(had ≥ 6 scores).
Peri-operative mortality
Ten observational studies involving a total of 1750 pa-
tients reported operative mortality. The odds ratios in the
study ranged from 0.16 to 2.32 (Fig. 2). The summary
odds ratio was 0.65 (95 % CI, 0.43-1.00), P = 0.05, indicat-
ing there was a reduced peri-operative mortality trend to-
wards repair, but no statistical significance reached. In
assessing potential heterogeneity across the studies, I2 =
0 %, and no publication bias was found either from the
Egger’s test (P = 0.83) or the Begg’s test (P = 0.68).
Late mortality
A total of nine studies (1622 Patients) reported late mor-
tality (Fig. 3). The overall hazard ratio was 0.87 (95 % CI,
0.67-1.14; P = 0.31), suggesting late mortality was not sig-
nificantly reduced following repair. Further, heterogeneity
was moderate (I2 = 30 %). It was noted that ten of the
studies included patients with different degrees of regurgi-
tation and left ventricular dysfunction, with exception
of one study [23], all of the patients included in this
study had severely impaired LV function (ejection
fraction <25 %) and severe ischemic MR undergoing
CABG. Severely decreased left ventricular function and se-
vere IMR could have the potential pathophysiological effect
on the mortality rates of those patients. Hence, sensitivity
analysis was conducted to only include studies in which not
all of the patients had severe ischemic MR and severely im-
paired LV function undergoing CABG. Restricting analysis
to these studies had no significant impact on the reduction
of late mortality following repair (the summary hazard ra-
tio, 1.03; 95 % CI, 0.90-1.17; P = 0.66). Whereas, heterogen-
eity suggested by I2 was significantly reduced to 0 %,
indicating no variability exists among the rest studies. Fur-
ther exclusion of any single study did not significantly re-
duce the heterogeneity. In addition, our study included 10
retrospective studies and 1 prospective study. The different
study designs may influence outcomes of meta-analysis.
Therefore, sensitivity analysis was performed to only in-
clude retrospective studies. Restricting analysis to these
studies did not significantly impact on the result for late
mortality (HR, 0.86; 95 % CI, 0.64-1.14; P = 0.30; I2 = 38 %).
Mitral valve reoperation
Reoperation due to such as MV regurgitation, thrombo-
embolism and prosthetic endocarditis was reported in
Fig. 1 Flow chart of study selection
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Table 1 Key Features of Included Studies







































244 244 66 66 73 69 41 41 36 35 12 13 NR NR 35 35 2.8 ± 0.5 2.8 ± 0.5 46.5bmo
Lio et al. 98 28 65 70d 74 61 81 89 35 32 NR NR 61 71 32 34 NR NR 45bmo
Ljubacev
et al.
34 41 NR NR NR NR 85 80 32 56d 26 17 NR NR NR NR NR NR In-hospital
Roshanali
et al.
26 31 57 57 83 77 NR NR NR NR NR NR NR NR 38 40 3.6 ± 0.5 3.5 ± 0.5 40.2a mo
Maltais
et al.
302 85 70 70 68 63 71 68 34 26 NR NR 85 91 34 34 NR NR 4.2ayrs
Qiu et al. 112 106 71 72 64 56 72 75 30 32 28 26 53 49 35 35 NR NR 48.1amo
Micovic
et al.
86 52 61b 62b 72 73 74 65 21 15 27 29 64 50 29 36 2.7 ± 0.6 2.5 ± 0.7 32a mo
Bonacchi
et al.
36 18 NR NR NR NR NR NR NR NR NR NR NR NR 27 27 NR NR 32a mo
Silberman
et al.
38 14 62 67d 74 93 50 57 45 57 NR NR 49cd 32cd <25 % NR NR 38amo
Mantovani
et al.
61 41 68 68 67 54 54 51 26 15 NR NR NR NR 45 45 3.1 ± 0.8 3.3 ± 0.7 36.8a mo
Reece
et al.
54 56 67 69 41d 68d NR NR 22 21 NR NR NR NR 44 40 NR NR In-hospital
a = mean; b = median; c Percentage class IV; d p < 0.05 between MVr and MVR
















































Lio et al. [10] 156 180 107 132 36 64 100 0 0 0 100 37 % open ring
63 % closed ring
37 % rigid ring
63 % semi-rigid ring
Ljubacev
et al. [24]
145 152 96 99 NR NR NR NR NR NR NR NR
Roshanali
et al. [28]
NR NR NR NR 100 0 100 0 0 NR NR NR
Maltais
et al. [13]




136 129 105 98 38 62 11 89 0 0 100 30 mm
Micovic
et al. [11]




NR NR NR NR NR NR 0 100 0 17 83 NR
Silberman
et al. [23]
154 184 99 111 100 0 NR NR NR 0 100 26 ± 1.2 mm
Mantovani
et al. [25]
179 173 131 122 76 24 0 100 0 0 100 Moderate
Reece
et al. [27]
112 132 152 171 NR NR NR NR NR 0 100 28 mm males
26 mm females
Abbreviations: MVP mitral valve repair, MVR mitral valve replacement, ACC time aortic cross-clamping time, CPB time, cardiopulmonary bypass time, NR
not reported






























Lorusso et al. 1 1 1 1 0 1 1 1 7
Lio et al. 1 1 1 1 1 1 1 1 8
Ljubacev et al. 1 1 1 1 0 1 0 1 6
Roshanali et al. 1 1 1 1 2 1 1 1 9
Maltais et al. 1 1 1 1 2 1 1 1 9
Qiu et al. 1 1 1 1 2 1 1 1 9
Micovic et al. 1 1 1 1 2 1 1 1 9
Bonacchi et al. 1 1 1 1 2 1 1 1 9
Silberman et al. 1 1 1 1 1 1 1 1 8
Mantovani et al. 1 1 1 1 2 1 1 1 9
Reece et al. 1 1 1 1 1 1 0 1 7
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five studies involving a total of 845 patients. The combined
odds ratio was 1.47, suggesting the trend went towards the
preference of replacement. Nevertheless, no significant dif-
ferences were reached between the two surgical approaches
(95 % CI, 0.90-2.38; I2 = 0 %; P = 0.12) (Fig. 4).
Recurrence of MR
Five studies involving a total of 837 patients provided
data regarding recurrence of MR during the follow-up.
The MVP + CABG group was associated with a signifi-
cantly increased recurrence rate of MR (OR, 5.41; 95 %
CI: 3.12–9.38; P < 0.001) with low heterogeneity among
those studies (I2 = 10 %) (Fig. 5). Sensitivity analysis was
also performed to only include retrospective studies.
Restricting analysis to these studies did not significantly
impact on the result for recurrence of MR (OR, 5.97;
95 % CI, 3.36-10.58; P < 0.001; I2 = 0 %).
Discussion
In our meta-analysis of eleven studies, which included
patients undergoing repair or replacement electively
with CABG surgery, no differences were found regarding
peri-operative mortality and long-term survival. Mitral
valve replacement was associated with lower incidence of
mitral regurgitation in patients with IMR during CABG.
The Society of Thoracic Surgeons reports MVP +CABG
group had approximately 5 % (4.8 % in-hospital mortality
and 5.3 % operative mortality) nationwide mortality rates in
contrast with 8 % (7.8 % in-hospital mortality and 8.5 % op-
erative mortality) for MVR+CABG group [29].
Moderate and severe recurrent MR after a restrictive
annuloplasty ring, occurred early and affected a substan-
tial proportion of patients by 2 years [30]. In the present
study, the main disadvantage of MVP + CABG group is
recurrence of MR compared to MVR + CABG group. Al-
though MR recurrence was common, mitral valve reop-
eration was not. Similar reoperation rate was found
between both groups, which suggested that not all pa-
tients with MR recurrence 2+ or greater needed reopera-
tion. There were several possible explanations. IMR after
annuloplasty might be considered inconsequential com-
pared with the underlying myocardial disease, or sur-
geons might be hesitant to perform a second or third
cardiac operation in these elderly, high-risk patients [31].
Fig. 2 Mitral valve repair versus mitral valve replacement on peri-operative mortality
Fig. 3 Mitral valve repair versus mitral valve replacement on late mortality
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Many patients with recurrent MR were just too sick or
too old or both to even consider reoperating on them.
A case-matched study found that replacement was asso-
ciated with lower incidence of valve-related complications
than was repair and both mitral valve procedures showed
no significant difference in LV function at follow-up [32].
However, replacement had greater thromboembolic and is-
chemic stroke rates than repair despite anticoagulant ther-
apy [33]. Although mitral valve replacement can sufficiently
correct regurgitation, the structural integrity of the mitral
valve is usually compromised after replacement, leading to
a continuous damage on the left ventricular tethered loop,
which results in adverse effects on left ventricular contrac-
tion and poor prognosis [8]. Therefore, individualized con-
sideration should be given to the two surgical procedures.
To date, there have been no RCTs that compared the
clinical outcomes of the two surgical management par-
ticularly in patients with chronic IMR during CABG. To
our knowledge, our report is the first meta-analysis com-
paring short-term and long-term outcomes of two mitral
valve procedures specifically on patients with chronic
IMR undergoing concomitant CABG. We selected studies
for this meta-analysis with rigorous inclusion and exclu-
sion criteria. All the patients in the studies underwent
concomitant CABG, which ensures homogeneity of IMR
patients and facilitates comparisons between trials. In
addition, patients with acute IMR due to ruptured papil-
lary muscles were excluded in our study, thus the
outcomes of this meta-analysis not only truly reflect the
surgical intervention of chronic IMR but also avoid bias-
ing the results toward worsening the replacement group.
By excluding articles that had > 20 % lack of annuloplasty
ring, we have made the comparison between the two mi-
tral valves surgeries more powerful. Therefore, the results
of our study truly reflect the surgical management of pa-
tients with IMR simultaneous to CABG.
Limitations
Our meta-analysis has several limitations. Firstly, this
study was based on observational, retrospective studies
with inherent bias of such study designs. The publications
included in this meta-analysis were relatively small and
nonrandomized studies. Secondly, changes in NYHA
class, LVEF and left ventricular reversal remodeling were
too scarcely reported in the included studies to enable
meta-analysis. Eight out of eleven studies included in our
meta-analysis reported data on the subvalvular apparatus
preservation in mitral valve replacement yet with lack of
uniform preservation of both the anterior and posterior
leaflets. The other three studies had no description regard-
ing subvalvular apparatus preservation. Thirdly, potential
confounding factors such as preoperative risk evaluation
(STS score i.e.), mitral valve more suitable for repair, age,
cause of mitral regurgitation (ischemia, fibrosis, ventricu-
lar remodeling), EF and complexity of revascularization
were not considered or adjusted in some of the studies
Fig. 4 Mitral valve repair versus mitral valve replacement on reoperation
Fig. 5 Mitral valve repair versus mitral valve replacement on recurrence of mitral valve regurgitation
Wang et al. Journal of Cardiothoracic Surgery  (2016) 11:141 Page 7 of 9
included in our meta-analysis. Therefore, the superiority of
repair over replacement may be affected by this and other
factors that are not possible to be revealed with meta-
analysis of observational trials. Well-designed RCTs are re-
quired to further verify the conclusion. Another limitation
of our report is the fact that follow-up periods were hetero-
geneous between some studies with different use of mean
and median durations of follow-up. Therefore, subgroup
analysis could not be performed statistically.
Conclusions
In patients with chronic ischemic mitral regurgitation
during CABG, mitral valve replacement is associated
with lower recurrence of regurgitation. No differences
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